Troglitazone

97322-87-7

C24H27NO5S

DMSO : >= 100 mg/mL (226.48 mM)

Cell Cycle/DNA Damage; Autophagy

Troglitazone is a PPARgamma agonist, with EC₅₀s of 550 nM and 780 nM for human and murine?PPARgamma receptor, respectively. IC50 & Target: EC50: 550 nM (Human PPARgamma), 780 nM (Murine PPARgamma)^[1] In Vitro: Troglitazone is a PPARgamma agonist, with EC₅₀s of 550 nM and 780 nM for human and murine?PPARgamma receptor, respectively^[1]. Troglitazone (2-200 uM) is cytotoxic to the pancreatic cancer cell lines (MIA Paca2 and PANC-1 cells), with IC₅₀s of 49.9?+/-?1.2 and 51.3?+/-?5.3 uM, respectively. Troglitazone (50 uM) increases chromatin condensation in MIA Paca2 and PANC-1 cells, enhances the activity of caspase-3 and decreases Bcl-2 expression^[2]. Troglitazone (0, 1, 2, and 4 uM) sensitizes TRAIL-mediated apoptosis in human lung adenocarcinoma cells. Troglitazone enhancement of TRAIL-induced apoptosis is blocked by inhibition of autophagy, via activation of autophagy flux. In addition, the effects of troglitazone are induced by PPARgamma activation in A549 cells^[3]. In Vivo: Troglitazone (200 mg/kg, p.o.) shows inhibitory effects on the growth of tumor in the MIA Paca2 xenograft model^[2].